Abstract
Chronic rhinosinusitis with nasal polyp (CRSwNP) can be controlled with medication or surgical treatment, yet limitations exist, and biologics can be an effective alternative for uncontrolled severe CRSwNP patients with poor response to traditional medication and multiple surgeries. In order to better understand the role of biologics in CRSwNP, pharmacokinetics and pharmacodynamics of monoclonal antibodies and local, systemic pathophysiology of CRSwNP in blood vessel, sinus mucosa, and nasal polyp are explored and explained in terms of pathomechanism of each biologic.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of Clinical Otolaryngology Head and Neck Surgery
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
